What’s New in MS Research – November 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article More evidence on the benefits of starting DMTs sooner rather than later Assessing the impact of Ocrevus® on patients with early-stage relapsing-remitting MS Investigational agent ublituximab lowers relapse rate in two Phase III studies Study details tolebrutinib efficacy, safety profile over 48 […]

Read News Article

What’s New in MS Research – September 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Encouraging results from Phase II study of tolebrutinib FDA authorizes stem cell trial focused on people with mild-to-moderate MS Long-term study shows sustained efficacy, consistent safety profile for Tecfidera® No short-term increase in relapse risk from Pfizer/BioNTech COVID vaccine, study finds Government […]

Read News Article

What’s New in MS Research – July 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Good cause to watch for anxiety and depression in the first year after MS diagnosis The case for “starting strong” with an initial disease-modifying therapy Positive results for the investigational disease-modifying therapy ublituximab Measuring the long-term effects of relapses in MS Exploring […]

Read News Article

What’s New in MS Research – May 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Do you and your neurologist attach the same importance to various DMT benefits and risks? Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis MRI findings yield clues to likelihood of MS worsening in pediatric patients Young and stressed over […]

Read News Article

What’s New in MS Research: March 2021

The first quarter of 2021 has been marked by welcome news on the medical front, and those hopeful developments aren’t limited to the increasing number of COVID-19 vaccinations being given across the country. Significant strides in treating and understanding MS also have been made in these early months of the year, as detailed in this edition of “What’s New in MS Research.”

Read News Article

What’s New in MS Research: January 2021

The expression, “Here’s hoping this year is better than the last” has particular poignancy as we transition into 2021. Happily, much of the recent news regarding multiple sclerosis (MS) provides cause for considerable hope, as reflected in the study results and other reports featured in this month’s iteration of “What’s New in MS Research.”

Read News Article

What’s New in MS Research – November 2020

While we all know “MS” stands for “multiple sclerosis,” with so much exciting research reported in this edition of “What’s New in MS Research,” we can almost imagine that “MS” could also refer to the quest for “multiple solutions” in MS. Although a great deal of the research looks to further understand the biology, easing the symptoms, and slowing or stopping the physical damage of MS, the studies and other information presented here are very encouraging – and they are only a small sample of the vast array of research under way around the world.

Read News Article

What’s New in MS Research: September 2020

This edition of MSAA’s “What’s New in MS Research” article features highlights from the annual meetings of the American Academy of Neurology (AAN) and the Consortium of MS Centers (CMSC). Because of the ongoing COVID-19 pandemic, both of these meetings were held virtually. While not all of the reports are positive, the good far outweighs the rest, and encompasses not only promising research advances in MS, but also a potential role for a long-established DMT in treating COVID-19.

Read News Article

What’s New in MS Research: November 2019

This edition of MSAA’s “What’s New in MS Research” provides highlights from this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Experts from throughout the world gathered in Stockholm, Sweden in mid-September to share and discuss the latest research into the causes, diagnosis, course, and treatment of multiple sclerosis.

Read News Article